Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov enrollment closed early-phase tilt small index

Leukaemia, Lymphocytic, Chronic: early-phase trial registry

A small indexed set (2 trials) with no open enrollment listed right now.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count

Leukaemia, Lymphocytic, Chronic: 2 US clinical trials tracked, none currently recruiting.

Leukaemia, Lymphocytic, Chronic is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 0 are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most active sponsor is Novartis Pharmaceuticals, running 1 of these trials.

Enrollment posture brief

Registry condition leukaemia-lymphocytic-chronic

OPEN 0 | RECR 0% | LATE 0 | EARLY 2 | RANK #7188 | SPON 1

Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)

Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%Leukaemia, Lymphocytic, (th…0%
Open-enrollment share among volume-matched conditions near Leukaemia, Lymphocytic, Chronic

Leukaemia, Lymphocytic, Chronic has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Leukaemia, Lymphocytic, Chronic on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Leukaemia, Lymphocytic, Chronic is recruiting below its size-band peers.

    0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 22

Phase Distribution

PhaseTrial count
Phase 2 2

Top Sponsors

Named interventions

Most-linked intervention names on Leukaemia, Lymphocytic, Chronic records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Ofatumumab 1000mg Drug
1 trials
Ofatumumab 500mg Drug
1 trials
Ofatumumab Biological
1 trials
Bendamustine Drug
1 trials
Fludarabine Drug
1 trials
Cyclophosphamide Drug
1 trials

US sites by state

Facility locations filed on Leukaemia, Lymphocytic, Chronic trials. A trial with sites in several states counts in each.

Utah 1 trials
Texas 1 trials
Tennessee 1 trials
Florida 1 trials
Colorado 1 trials
Arizona 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Leukaemia, Lymphocytic, Chronic page

2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • No Leukaemia, Lymphocytic, Chronic trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Novartis Pharmaceuticals sponsors the most Leukaemia, Lymphocytic, Chronic trials on record, review their full trial history before evaluating a specific study. See Novartis Pharmaceuticals's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Leukaemia, Lymphocytic, Chronic condition card totals 2 registered trials; most-linked intervention Ofatumumab 1000mg; top US site state Utah. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.